Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals' pneumococcal vaccines (2830929A and 2830930A) administered as a 3-dose primary vaccination course during the first 6 months of life and as a booster dose at 12-15 months of age.

Trial Profile

A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals' pneumococcal vaccines (2830929A and 2830930A) administered as a 3-dose primary vaccination course during the first 6 months of life and as a booster dose at 12-15 months of age.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2830929A (Primary) ; Pneumococcal vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Pneumococcal 10-valent vaccine conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Hepatitis B; Influenza B virus infections; Pertussis; Pneumonia; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Acronyms SPNG-009
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 25 Apr 2017 Results (n=890) assessing differences in immune responses to PCV13 and PCV10 using patient data from NCT01204658, NCT01616459 and NTR3069 trials, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 06 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 09 Aug 2013 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top